Vistin Pharma plans to raise up to Nkr300m ($38.82m) in gross proceeds through a private placement of shares of its common stock.

The company will divest 26,785,715 shares to Norwegian and international investors and has received significant pre-commitments.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The proceeds are intended to be used for setting up energy trading business and trading activities.

Vistin Pharma is a Norway-based active pharmaceutical ingredients (API) provider.

“China Traditional Chinese Medicine Holdings plans to raise approximately HK$2.67bn ($341.3m).”

Shenzhen Neptunus Bioengineering is planning to make a public offering of short-term financing bonds to raise CNY2bn ($315.58m) in gross proceeds.

The proceeds are intended to be used to repay loans from financial institutions and to supplement working capital.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Shenzhen Neptunus manufactures and distributes pharmaceutical products.

China Traditional Chinese Medicine Holdings plans to raise approximately HK$2.67bn ($341.3m) in gross proceeds through the private placement of shares.

The company will place 604.3 million shares priced at HK$4.43 ($0.56) a share, as part of the transaction.

Ping An Life Insurance Company of China has subscribed to the placement.

The proceeds are intended to be used to expand the company’s traditional Chinese medicine business, as well as to make acquisitions, repay debts, supplement working capital, and for research and development (R&D).

China Traditional Chinese Medicine Holdings is based in Hong Kong.

Pharmaceutical Technology Excellence Awards - Nominations Closed

Nominations are now closed for the Pharmaceutical Technology Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Awarded the 2025 Pharmaceutical Technology Excellence Award for Business Expansion in Integrated Manufacturing, Upperton Pharma Solutions is rapidly expanding its UK GMP and sterile manufacturing footprint. Find out how Upperton’s integrated CDMO model helps pharma companies move from early development to clinical and niche commercial supply with fewer handovers and faster timelines.

Discover the Impact